ABCMdb

PMID: 10698967

Lee CG, Ramachandra M, Jeang KT, Martin MA, Pastan I, Gottesman MM
Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter.
FASEB J. 2000 Mar;14(3):516-22., [PubMed]

Sentences

No. Mutations Sentence Comment

21 ABCB1 p.Asp555Asn ABCB1 p.Asp555Asn MDR1mt contains the mutant residue Asn in place of Asp at position 555 of the molecule (D555N). Login to comment 41 ABCB1 p.Asp555Asn Target HeLa cells were coinfected with VCB3 (CD4-expressing vv), VTF7-3 (vv expressing T7 RNA polymerase), and either of the following vv: WR (wild-type control), MDR1, D555N (amino-terminal ATP binding site mutant of MDR1), V185 (substrate mutant of MDR1 that changes substrate specificity of MDR1) (18), or CFTR (19). Login to comment 58 ABCB1 p.Asp555Asn Bicistronic constructs expressing either wild-type (wt) MDR1 or MDR1 mutated (D555N) at the ATP utilization site (mt) to inactivate P-gp pump function and DHFR were stably introduced into 12D7 cells by selection with methotrexate (24, 25). Login to comment 82 ABCB1 p.Gly185Val ABCB1 p.Asp555Asn Similar results were seen in five independent experiments. Figure 3 shows that fusion was greatly reduced in target cells expressing either wt MDR1, MDR1 with an inactivating amino-terminal ATP-utilization site (D555N) mutation that renders the transporter inactive or MDR1 with a single mutation in the substrate binding site (G185V) (18). Login to comment 96 ABCB1 p.Gly185Val ABCB1 p.Asp555Asn WR: wild-type control; MDR1: wild-type MDR1; D555N: amino-terminal ATP binding site mutant of MDR1; G185V; substrate mutant of MDR1 that changes the substrate specificity; CFTR: cystic fibrosis transmembrane regulator. Login to comment 152 ABCB1 p.Asp555Asn We wish to thank J. A. Hoxie (University of Pennsylvania) for providing 12G5 CXCR4 antibody; Y. Sugimoto (Japanese Foundation for Cancer Research) for providing biotinylated MRK16-Fab antibody; G. Englund (NIAID) for help with the three-color FACS analyzes; K. Strebel (NIAID) for help with fluorescence microscopy; C. A. Hrycyna (NCI) for providing the D555N cDNA, for further construction of the pHMIDmt, and the generation of recombinant vaccinia viruses; E. A. Berger (NIAID) for providing VCB3, VTF7-3, VCB21, VCB16, and VCB60 vaccinia viruses; M. Welsh (University of Iowa College of Medicine) for the CFTR vaccinia virus; and Y. Raviv and R. Blumenthal (NCI-Frederick) for discussions and data sharing. Login to comment